Did the Amgen CEO Get a Raise?
No — pay was essentially flat. Robert Bradway's total compensation was essentially unchanged at $12.0M in 2025, from $12.0M in 2024, per Amgen's SEC DEF 14A filings.
This page answers a common executive-compensation question: Did the Amgen CEO Get a Raise?. The answer draws on SEC DEF 14A proxy statements, the public disclosure mechanism for U.S. public-company executive pay. Every public company must file an annual proxy statement disclosing CEO and named-executive-officer compensation in detail. Why this matters for shareholders: executive compensation is the single most-disclosed governance metric at U.S. public companies, and the Dodd-Frank-mandated say-on-pay vote gives shareholders an explicit channel to express approval or dissent. Reading pay data well — including pay-versus-performance, peer-group selection, and time-vesting structures — is a basic part of stock-by-stock fundamental analysis.
The detailed answer below uses the actual proxy-statement filings, explains how to read them, and translates the executive-compensation accounting into the shareholder-relevant interpretation.
Robert Bradway Pay: 2024 → 2025
- 2025 total comp
- $12,000,000
- 2024 total comp
- $12,000,000
- Change ($)
- +$0
- Change (%)
- +0%
Source: Amgen SEC DEF 14A proxy statements, 2024 and 2025 Summary Compensation Tables.
In its latest proxy statement, Amgen reported Robert Bradway's 2025 total compensation at $12,000,000 — essentially flat versus $12,000,000 in 2024.
Across the disclosed history, Robert Bradway's total pay has run: 2022, $12.0M; 2023, $12.0M; 2024, $12.0M; 2025, $12.0M. CEO compensation is lumpy year to year because equity grants — the largest component — are often awarded in multi-year blocks rather than evenly, so a single year's jump or drop can reflect grant timing as much as a change in pay philosophy.
Whether a raise is warranted ties back to performance: Amgen posted a 8.3% three-year total shareholder return on 3.5% revenue growth, and the package carries a CEOPay Pay-for-Performance grade of B (70/100).
Compensation Detail
| Component | Amount |
|---|---|
| Total Compensation | $12,000,000 |
| Base Salary | $1,200,000 |
| Stock Awards | $6,000,000 |
| Option Awards | $1,440,000 |
| Non-Equity Incentive | $1,800,000 |
| CEO-to-Worker Pay Ratio | 96:1 |
| Pay-Performance Grade | B |
Other Biotechnology CEOs
Frequently Asked Questions
No — pay was essentially flat. Robert Bradway's total compensation was essentially unchanged at $12.0M in 2025, from $12.0M in 2024, per Amgen's SEC DEF 14A filings.
Robert Bradway, CEO of Amgen, earned $12.0M in total compensation in 2025, including $6.0M in stock awards and $1,200,000 in base salary.
In 2025, total compensation of $12,000,000 was composed of $1,200,000 base salary, $0 cash bonus, $6,000,000 stock awards, $1,440,000 option awards, and $1,800,000 in non-equity incentive compensation.
Our Pay-for-Performance Score rates Amgen as B (70/100), based on three-year total shareholder return of 8.3%, revenue growth of 3.5%, and shareholder say-on-pay vote approval.
Robert Bradway is the chief executive officer of Amgen (AMGN).
More about Amgen
No — pay was essentially flat. Robert Bradway's total compensation was essentially unchanged at $12.0M in 2025, from $12.0M in 2024, per Amgen's SEC DEF 14A filings.
Source: SEC EDGAR DEF 14A proxy statements, 2026.